A new drug combination, enfortumab vedotin in combination with pembrolizumab, has been found to significantly reduce the risk of death in patients with advanced bladder cancer. The treatment improved median overall survival by over 15 months and almost doubled the length of median progression-free survival compared to standard chemotherapy. The Phase 3 trial involved 886 patients and showed promising results, with a 53% reduced risk of death and a 68% confirmed objective response rate. The combination of enfortumab vedotin and pembrolizumab has the potential to revolutionize the treatment of advanced urothelial cancer and provide much-needed new therapies for patients.
Source link
New drug combination reduces risk of death in advanced bladder cancer cases by 53 per cent
